# VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...

> **NCT00858611** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 51 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** VRC-FLUDNA047-00-VP
- **DRUG:** Flulaval (Registered) Seasonal Influenza Vaccine

## Key facts

- **NCT ID:** NCT00858611
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-03
- **Primary completion:** 2010-06-21
- **Final completion:** 2010-06-21
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858611, "VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00858611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*